 |  |  |  |
|---|---|---|---|
 |
Welcome!
The Cancer Discovery Hub (CDH) is a one-stop pan-omics diagnostic and research core laboratory housed at the National Cancer Centre Singapore. We specialise in state-of-the-art research-grade technologies and provide expert support to investigators on all cancer related projects.
Latest news
Key events and achievements
-
12 Dec 2022: Oral abstract, ASH Annual Meeting, New Orleans, USA
-
09 Dec 2022: Invited presentation, Stem Cell Society Singapore (SCSS) Symposium (Nimmi Baby)
-
17 Nov 2022 : Oral paper, CTOS Annual Meeting, Vancouver, Canada (Jui Wan LOH, Jing Yi LEE)
-
19 Aug 2022 : Invited speech, 6th International BRCA Forum, Singapore
-
Precision Oncology: The Time is Now !
-
-
19 Aug 2022 : Collaborative research agreement with Scinnohub Pharmaceutical
-
19 Aug 2022 : Collaborative research agreement with MGI Tech
-
04 Aug 2022 : Collaborative research agreement with Twist Bioscience
-
16 Jun 2022 : Best Oral Presentation, International Congress of the Asian Oncology Society (AOS 2022), South Korea
-
ctDNA mutations in progressive gastrointestinal stromal tumors identify drug resistance biomarkers and uncover potential therapeutic strategies (Tun Kiat KO)
-
-
12 Apr 2022 : Invited Oral Presentation at Major Symposium, AACR Annual Meeting, New Orleans
-
Identification and characterization of human angiosarcoma subtypes through multi-omic multi-dimensional profiling
-
-
22 Feb 2022 : Publication on circulating tumor DNA mutations in progressive gastrointestinal stromal tumors, Frontiers in Oncology
-
17 Feb 2022 : Travel Award for Poster abstract at Japanese Society of Medical Oncology Annual Meeting, Japan
-
Dissecting Intratumoral Heterogeneity of Sarcomatoid RCC Arising from Autosomal Dominant Polycystic Kidney Disease (Elizabeth LEE)
-
-
15 Feb 2022 : Identification of fibroblasts as key secretors of PAI-I using single cell sequencing, published in Cell Reports Medicine
-
12 Jan 2022 : Commercial launch of the UNITED NGS Assay (Lucence) for Asian prevalent cancers at the NCCS
-
21 Oct 2021 : Collaborative research agreement with STEMCELL Technologies
-
01 Sep 2021 : Collaborative research agreement with SymBio Pharmaceuticals on EBV-positive lymphomas
-
01 Sep 2021 : Official launch of Cancer Discovery Hub!
Start a project consultation with us
Featured Publications
Scientific publications supported by the Cancer Discovery Hub
HER2 expression, copy number variation and survival outcomes in HER2-low non-metastatic breast cancer: an international multicentre cohort study and TCGA-METABRIC analysis
BMC Medicine. 2022
Mar, 2022
HER2-low breast cancer (BC) is currently an area of active interest. This study evaluated the impact of low expression of HER2 on survival outcomes in HER2-negative non-metastatic breast cancer (BC). Patients with HER2-negative non-metastatic BC from 6 centres within the Asian Breast Cancer Cooperative Group (ABCCG) (n = 28,280) were analysed. Results: ABCCG cohort median follow-up was 6.6 years; there were 12,260 (43.4%) HER2-low BC and 16,020 (56.6%) HER2-zero BC. The outcomes were better in HER2-low BC than in HER2-zero BC (RFS: centre-adjusted hazard ratio (HR) 0.88, 95% CI 0.82-0.93, P < 0.001; OS: centre-adjusted HR 0.82, 95% CI 0.76-0.89, P < 0.001). On multivariable analysis, HER2-low status was prognostic (RFS: HR 0.90, 95% CI 0.85-0.96, P = 0.002; OS: HR 0.86, 95% CI 0.79-0.93, P < 0.001). These differences remained significant in hormone receptor-positive tumours and for OS in hormone receptor-negative tumours. Superior outcomes were observed for HER2 IHC1+ BC versus HER2-zero BC (RFS: HR 0.89, 95% CI 0.83-0.96, P = 0.001; OS: HR 0.85, 95% CI 0.78-0.93, P = 0.001). Conclusions: HER2-low BC had a superior prognosis compared to HER2-zero BC in the non-metastatic setting, though absolute differences were modest and driven by HER2 IHC 1+ BC. ERBB2 CNV merits further investigation in HER2-negative BC.